ArticleJournal of translational medicine2026
Single-cell analysis reveals an endothelial TP53-CXCL14 axis in breast cancer progression.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe TME of BRCA plays a core role in disease progression and treatment resistance. As a pleiotropic chemokine, CXCL14 exhibits context-dependent roles in cancer. While its potential prognostic value in BRCA has been noted, its precise role and regulatory mechanisms remain elusive.
methodThe expression of CXCL14, its prognostic significance, and its association with the immune microenvironment were systematically analyzed using public databases, such as TCGA, GEO, and cBioPortal. In vitro experiments were performed to generate HUVEC cells with stable TP53 silencing or overexpression. ChIP-qPCR and dual-luciferase reporter assays were used to assess TP53's effect on CXCL14 transcriptional regulation. In vivo tumor growth was evaluated in a xenograft mouse model co-injected with HUVECs and MDA-231 cells.
resultsHigh expression of CXCL14 was significantly associated with rounding down for 4 and rounding up for 5 indicators, such as favorable OS (HR = 0.64, P = 0.006), and PFS (HR = 0.65, P = 0.002) in BRCA patients, and indicated a better response to immune checkpoint inhibitor treatment. Its expression is associated with a remodeled immune microenvironment, characterized by an increase in the infiltration of anti-tumor immune cells (e.g., CD8⁺T cells) and a decrease in immunosuppressive cells (e.g., M2 macrophages). ScRNA-seq analysis identified ECs as the main cellular source of CXCL14 in the TME for the first time. Mechanistic analyses indicated that mutant TP53 binds the CXCL14 promoter, supporting transcriptional repression. Functional experiments confirmed that the secretion of CXCL14 by TP53-mutated ECs decreased, thereby promoting the migration and invasion of BRCA cells. In vivo, co-injection of TP53-mutant (R175H) HUVECs with BRCA cells resulted in significantly larger and heavier tumors, accompanied by increased Ki-67 staining and decreased CXCL14 expression, compared to the wild-type TP53 group.
conclusionOur findings indicate that CXCL14 serves as a promising independent prognostic factor associated with an anti-tumor immune microenvironment in BRCA, with ECs identified as a major source. Furthermore, TP53 mutations may promote BRCA progression by repressing endothelial through CXCL14 transcription.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.